ArticleOncotarget2015

Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.

Afua Adjeiwaa Mensah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.